-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Downgrades Artiva Biotherapeutics to Neutral, Lowers Price Target to $4

Benzinga·10/27/2026 14:12:10
Wedbush analyst David Nierengarten downgrades Artiva Biotherapeutics (NASDAQ:ARTV) from Outperform to Neutral and lowers the price target from $40 to $4.